151 related articles for article (PubMed ID: 24127184)
1. Treatment with anti–tumor necrosis factor biologic agents in human T lymphotropic virus type I–positive patients with rheumatoid arthritis.
Umekita K; Hidaka T; Miyauchi S; Ueno S; Kubo K; Takajo I; Hashiba Y; Kai Y; Nagatomo Y; Okayama A
Arthritis Care Res (Hoboken); 2014 May; 66(5):788-92. PubMed ID: 24127184
[TBL] [Abstract][Full Text] [Related]
2. Brief Report: Attenuated Effectiveness of Tumor Necrosis Factor Inhibitors for Anti-Human T Lymphotropic Virus Type I Antibody-Positive Rheumatoid Arthritis.
Suzuki T; Fukui S; Umekita K; Miyamoto J; Umeda M; Nishino A; Okada A; Koga T; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Fujikawa K; Aramaki T; Mizokami A; Matsuoka N; Ueki Y; Eguchi K; Sato S; Hidaka T; Origuchi T; Okayama A; Kawakami A; Nakamura H
Arthritis Rheumatol; 2018 Jul; 70(7):1014-1021. PubMed ID: 29471588
[TBL] [Abstract][Full Text] [Related]
3. Use of anti-tumor necrosis factor biologics in the treatment of rheumatoid arthritis does not change human T-lymphotropic virus type 1 markers: a case series.
Umekita K; Umeki K; Miyauchi S; Ueno S; Kubo K; Kusumoto N; Takajo I; Nagatomo Y; Okayama A
Mod Rheumatol; 2015 Sep; 25(5):794-7. PubMed ID: 24252020
[TBL] [Abstract][Full Text] [Related]
4. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
Matsudaira R; Tamura N; Sekiya F; Ogasawara M; Yamanaka K; Takasaki Y
J Rheumatol; 2011 Nov; 38(11):2346-54. PubMed ID: 21965648
[TBL] [Abstract][Full Text] [Related]
5. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug.
Söderlin MK; Petersson IF; Geborek P
Scand J Rheumatol; 2012 Feb; 41(1):1-9. PubMed ID: 22118371
[TBL] [Abstract][Full Text] [Related]
6. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis.
Bos WH; Bartelds GM; Wolbink GJ; de Koning MH; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Nurmohamed MT
J Rheumatol; 2008 Oct; 35(10):1972-7. PubMed ID: 18785316
[TBL] [Abstract][Full Text] [Related]
7. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
8. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
Quartuccio L; Fabris M; Salvin S; Atzeni F; Saracco M; Benucci M; Cimmino M; Morassi P; Masolini P; Pellerito R; Cutolo M; Puttini PS; De Vita S
Rheumatology (Oxford); 2009 Dec; 48(12):1557-9. PubMed ID: 19789202
[TBL] [Abstract][Full Text] [Related]
9. Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis.
Savioli C; Ribeiro AC; Fabri GM; Calich AL; Carvalho J; Silva CA; Viana VS; Bonfá E; Siqueira JT
J Clin Rheumatol; 2012 Jun; 18(4):180-4. PubMed ID: 22647860
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.
Fernández-Nebro A; Irigoyen MV; Ureña I; Belmonte-López MA; Coret V; Jiménez-Núñez FG; Díaz-Cordovés G; López-Lasanta MA; Ponce A; Rodríguez-Pérez M; Calero E; González-Santos P
J Rheumatol; 2007 Dec; 34(12):2334-42. PubMed ID: 17985409
[TBL] [Abstract][Full Text] [Related]
11. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
Benucci M; Turchini S; Parrochi P; Boccaccini P; Manetti R; Cammelli E; Manfredi M
Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
[TBL] [Abstract][Full Text] [Related]
12. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis.
Blom M; Kievit W; Donders AR; den Broeder AA; Straten VH; Kuper I; Visser H; Jansen TL; Brus HL; Branten AJ; van de Laar MA; van Riel PL
J Rheumatol; 2011 Nov; 38(11):2355-61. PubMed ID: 21885487
[TBL] [Abstract][Full Text] [Related]
14. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor alpha inhibitors have no effect on a human T-lymphotropic virus type-I (HTLV-I)-infected cell line from patients with HTLV-I-associated myelopathy.
Fukui S; Nakamura H; Takahashi Y; Iwamoto N; Hasegawa H; Yanagihara K; Nakamura T; Okayama A; Kawakami A
BMC Immunol; 2017 Feb; 18(1):7. PubMed ID: 28158970
[TBL] [Abstract][Full Text] [Related]
17. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
[TBL] [Abstract][Full Text] [Related]
18. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PL; Nordström DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF
Ann Rheum Dis; 2011 Sep; 70(9):1575-80. PubMed ID: 21571731
[TBL] [Abstract][Full Text] [Related]
19. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
20. Sex hormone concentrations in patients with rheumatoid arthritis are not normalized during 12 weeks of anti-tumor necrosis factor therapy.
Straub RH; Härle P; Atzeni F; Weidler C; Cutolo M; Sarzi-Puttini P
J Rheumatol; 2005 Jul; 32(7):1253-8. PubMed ID: 15996060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
